EUVIMEDEUVIMED entdecken
Crossref

Surfactant therapy using a bronchofiberscope in respiratory distress syndrome

Masanori Wasa iD, Hisaya Hasegawa, Hirotaka Kihara, Yosuke Yamada iD, Masae Mizogami iD, Rei Kitamura, Kenta Ikeda

Pediatrics International · 2023

DOI: 10.1111/ped.15478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatrics International, 2023. Verfasst von Masanori Wasa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Respiratory Distress Syndrome, Newborn, Pulmonary Surfactants. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Avoiding endotracheal intubation and using nasal continuous positive airway pressure as the initial treatment is recommended in infants with respiratory distress syndrome (RDS), and modes of lesser invasive surfactant administration have recently been reported. We report a pilot study assessing the feasibility of surfactant therapy using a bronchofiberscope (STUB) in RDS.

Methods

Surfactant was administered to 31 preterm infants (gestational age range of 28 weeks 0 days to 36 weeks 6 days) diagnosed with RDS, through the working channel of the bronchofiberscope or endotracheal tubes. Patient characteristics, outcomes, adverse events, and comorbidities were assessed in the two groups.

Results

Twelve infants received STUB. Two of the 12 infants (17%) needed subsequent intubation and additional surfactant administration. Nineteen infants received surfactant through endotracheal tubes. Four of the 19 infants (21%) required additional surfactants. There was no significant difference in the number of infants that needed additional surfactant ( p = 1.00). Gestational age, birthweight, length of hospitalization, adverse events, such as desaturations and bradycardias, and comorbidities were similar between the two groups. Days of invasive ventilation were significantly shorter in the STUB group ( p = 0.0002).

Conclusion

STUB was feasible in this small cohort and reduced the need for intubation to 17%, leading to fewer days of invasive ventilation, without increasing comorbidities and adverse events. To the best of our knowledge, this is the first study to administer surfactants using bronchofiberscopes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Distress Syndrome, NewbornPulmonary SurfactantsInfantInfant, NewbornHumansInfant, PrematureSurface-Active AgentsPilot ProjectsContinuous Positive Airway PressureLipoproteins

Stichwörter der Autor:innen

bronchofiberscopepreterm infantrespiratory distress syndromesurfactant

Substanzen

Surface-Active AgentsPulmonary SurfactantsLipoproteins

Autor:innen und Institutionen

  • Department of Neonatology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
  • Department of Pediatrics, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.

ORCID-Profile: Masanori Wasa, Yosuke Yamada, Masae Mizogami

Zitieren

APA

Wasa, M., Hasegawa, H., Kihara, H., Yamada, Y., Mizogami, M., Kitamura, R., & Ikeda, K. (2023). Surfactant therapy using a bronchofiberscope in respiratory distress syndrome. Pediatrics International. https://doi.org/10.1111/ped.15478

Vancouver

Wasa M, Hasegawa H, Kihara H, Yamada Y, Mizogami M, Kitamura R, et al. Surfactant therapy using a bronchofiberscope in respiratory distress syndrome. Pediatrics International. 2023. doi:10.1111/ped.15478

BibTeX
@article{Wasa2023,
  author = {Wasa, Masanori and Hasegawa, Hisaya and Kihara, Hirotaka and Yamada, Yosuke and Mizogami, Masae and Kitamura, Rei and Ikeda, Kenta},
  title = {Surfactant therapy using a bronchofiberscope in respiratory distress syndrome},
  journal = {Pediatrics International},
  year = {2023},
  doi = {10.1111/ped.15478}
}
Kostenlos starten →